Jennifer Grabowsky, PharmD
Volunteer Assistant Clinical Professor
Clinical Pharmacy
School of Pharmacy

Publications (11)

Top publication keywords:
BRCA1 ProteinPharmacistsHerb-Drug InteractionsIndazolesIndolesSulfonamidesDrug InteractionsPyrimidinesPhthalazinesCarcinoma, NeuroendocrineSirolimusNeoplasmsHistone Deacetylase InhibitorsBRCA2 ProteinFood-Drug Interactions

• A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2026 Chen J, Oberheim Bush NA, Grabowsky JA, Kline C, Kroetz DL, Taylor JW, Villanueva-Meyer J, Molinaro AM, de Groot JF, Butowski NA, Tedesco M, Rabbitt J, Phillips JJ, Hervey-Jumper S, Aghi MK, Berger MS…
• Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
  JCO precision oncology 2024 Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN
• Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
  JCO precision oncology 2024 Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P
• Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
  British journal of cancer 2023 Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK
• A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
  Cancer research communications 2022 Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN

Show all (6 more) Hide

• Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN
• Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN
• A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
  Cancer 2015 Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN
• Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, …
• Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
  Cancer chemotherapy and pharmacology 2014 Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P
• Drug interactions and the pharmacist: focus on everolimus.
  The Annals of pharmacotherapy 2013 Grabowsky JA